IBER.U (Ibere Pharmaceuticals) EBIT : $-1.04 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Ibere Pharmaceuticals EBIT?

Ibere Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2022 was $-0.23 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.04 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ibere Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2022 was -0.68%. Ibere Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Ibere Pharmaceuticals EBIT Historical Data

The historical data trend for Ibere Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibere Pharmaceuticals EBIT Chart

Ibere Pharmaceuticals Annual Data

Trend

Dec20

Dec21

EBIT

-1.00

Ibere Pharmaceuticals Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EBIT	Get a 7-Day Free Trial			-0.32	-0.36	-0.30	-0.14	-0.23

Competitive Comparison of Ibere Pharmaceuticals's EBIT

For the Shell Companies subindustry, Ibere Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ibere Pharmaceuticals's EV-to-EBIT Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Ibere Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ibere Pharmaceuticals's EV-to-EBIT falls into.

Ibere Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.04 Mil.

Ibere Pharmaceuticals (NYSE:IBER.U) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ibere Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2022 is calculated as:

	ROC % (Q: Sep. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2022 )	+	Invested Capital (Q: Sep. 2022 ))	/ count )
=	-0.936 * ( 1 - 0% )	/	( (138.268	+	139.001)	/ 2 )
=	-0.936	/	138.6345
=	-0.68 %

where

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	138.385	-	0.239	-	( 0.093	-	max(0, 0.398	-	0.276	+	0.093	))
=	138.268

	Invested Capital		(Q: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	138.955	-	0.31	-	( 0.004	-	max(0, 0.469	-	0.113	+	0.004	))
=	139.001

Note: The Operating Income data used here is four times the quarterly (Sep. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Ibere Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2022		Q: Sep. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.936	/	( ( (0 + max(-0.056, 0))	+	(0 + max(-0.201, 0)) )	/	2 )
=	-0.936	/	( ( 0	+	0 )	/	2 )
=	-0.936	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.183)	-	(0.239	+	0	+	0)
=	-0.056

	Working Capital		(Q: Sep. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.109)	-	(0.31	+	0	+	0)
=	-0.201

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ibere Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2022 )
	=	-1.038	/	0.000
	=	%

Ibere Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Ibere Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Ibere Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Ibere Pharmaceuticals (NYSE:IBER.U) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2005 Market Street, Suite 2030, Philadelphia, PA, USA, 19103

Website

https://www.iberepharma.com

Ibere Pharmaceuticals is a blank check company.

Executives

Elaine V Jones	director	C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Osagie O Imasogie	director, 10 percent owner, officer: Chief Executive Officer
Calvin B. Johnson	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Zoltan Kerekes	director, 10 percent owner, officer: Chief Operating Officer	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Louis J. Vollmer	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Lisa M. Gray	director, 10 percent owner, officer: Chief Financial Officer	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Henrietta Ukwu	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Pipv Capital Llc	10 percent owner	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103

Ibere Pharmaceuticals Headlines

From GuruFocus

Ibere Pharmaceuticals Receives Expected NYSE Notice Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 05-28-2021

Ibere Pharmaceuticals Announces Closing of $138,000,000 Initial Public Offering

By PRNewswire PRNewswire • 03-03-2021